Vaxcyte Chief Medical Officer Jodar Luis received 52,632 shares at $0 per share on Sep 4, 2026, and received 88,254 derivative securities through the same award transaction. The grant left him with 52,632 shares and 88,254 derivative securities, giving investors a clear view of the reported holdings.
Key Highlights
- Jodar Luis received 88,254 Vaxcyte derivative securities on Sep 4, 2026.
- The 52,632-share award represented about 100.0% of Luis’s resulting share holding.
- The filing lists transaction code A for the share award.
Vaxcyte, Inc. (NASDAQ: PCVX) awarded Chief Medical Officer Jodar Luis 52,632 shares at $0 per share. The award was recorded on Sep 4, 2026, and Luis’s resulting holding was 52,632 shares.
Award Details
The transaction carried code A, and the filing reports the shares at $0 per share. The filing reports 88,254 derivative securities of Vaxcyte awarded to Luis. Luis’s resulting holding of derivative securities after that transaction was 88,254. The share transaction represented about 100.0% of Luis’s resulting share holding. The share award and derivative-securities award were reported on the same date, Sep 4, 2026. The filing reports both the direct share award and the derivative-securities award associated with Luis.
FAQs
Q: How many Vaxcyte shares did Jodar Luis receive?
A: Jodar Luis received 52,632 Vaxcyte shares at $0 per share. His resulting share holding was also reported as 52,632 shares.
Q: What does the Vaxcyte executive share award mean for PCVX investors?
A: The transaction record identifies a 52,632-share award to Chief Medical Officer Jodar Luis. It also records 88,254 derivative securities held after the transaction.
Q: How many derivative securities did Jodar Luis receive from Vaxcyte?
A: The filing states that Jodar Luis received 88,254 Vaxcyte derivative securities on Sep 4, 2026. It reports that he owned 88,254 derivative securities following the transaction, representing about 100.0% of his resulting derivative-securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.